SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-076134
Filing Date
2021-06-03
Accepted
2021-06-03 09:00:48
Documents
12
Period of Report
2021-06-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2118359d1_8k.htm   iXBRL 8-K 33991
  Complete submission text file 0001104659-21-076134.txt   211526

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20210601.xsd EX-101.SCH 3184
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20210601_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20210601_pre.xml EX-101.PRE 22709
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2118359d1_8k_htm.xml XML 3636
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 21991363
SIC: 2834 Pharmaceutical Preparations